Physician profile
John Lobo
NPI 1962512699
$2,047.03
in general payments reported to CMS, 2019-2025
29 companies · $829 in 2025
The $829 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $67.83 · 2020: $19.88 · 2021: $24.11 · 2022: $138 · 2023: $612 · 2024: $357 · 2025: $829.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,797.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,797.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $382.87 | 2023-2025 | Xtandi, Myrbetriq |
| Boston Scientific Corporation | $180.46 | 2019-2025 | Rezum Generator, Spaceoar Vue System - 10ml |
| Medtronic, INC. | $156.58 | 2025 | Interstim |
| Teleflex LLC | $142.50 | 2022-2023 | Urolift |
| Sumitomo Pharma America, INC. | $130.47 | 2023-2025 | Orgovyx |
| Coloplast Corp | $104.87 | 2025 | |
| Accord Healthcare, INC. | $77.62 | 2024-2025 | |
| Abbvie INC. | $75.44 | 2024-2025 | |
| Axonics, INC. | $68.97 | 2021-2024 | Axonics |
| Tolmar, INC. | $68.44 | 2024-2025 | Eligard, Jatenzo |
| Pfizer INC. | $59.27 | 2022-2025 | |
| Verity Pharmaceuticals INC. | $57.97 | 2023-2025 | Trelstar |
| Antares Pharma, INC. | $54.20 | 2023-2025 | Xyosted, Tlando, Nocdurna |
| Myriad Genetic Laboratories, INC. | $53.10 | 2023 | Prolaris |
| Ferring Pharmaceuticals INC. | $48.18 | 2024 | Adstiladrin |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $39.46 | 2024 | Itind System |
| Neotract INC. | $39.00 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $38.57 | 2024-2025 | |
| Photocure INC | $38.53 | 2023-2024 | Cysview |
| C. R. Bard, INC. & Subsidiaries | $32.11 | 2025 | Personal Catheter Intermittent Catheter |
| Janssen Scientific Affairs, LLC | $29.86 | 2025 | Erleada |
| Progenics Pharmaceuticals, INC. | $26.85 | 2023 | Pylarify |
| Blue Earth Diagnostics | $24.86 | 2024 | |
| Halozyme INC | $22.98 | 2023 | |
| Endo Pharmaceuticals INC. | $22.51 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $21.77 | 2025 | Onglyza |
| Laborie Medical Technologies Corp. | $20.66 | 2025 | Optilume Bph Drug Coated Balloon Catheter |
| Bayer Healthcare Pharmaceuticals INC. | $14.63 | 2019 | |
| Endo USA, INC. | $14.30 | 2025 | Xiaflex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Lobo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.